Lexaria Bioscience Secures $4 Million Through Registered Direct Offering to Advance Drug Delivery Technology

Lexaria Bioscience Corp. has entered into a definitive agreement for a registered direct offering priced at-the-market under Nasdaq rules. The company will sell 2,666,667 shares of common stock at $1.50 per share, generating expected gross proceeds of approximately $4.0 million. This financing arrangement represents a strategic move to strengthen the company's financial position as it continues developing its proprietary drug delivery technologies.

In a concurrent private placement, Lexaria will issue unregistered warrants to purchase up to 2,666,667 additional shares of common stock. These warrants carry an exercise price of $1.37 per share and are immediately exercisable upon effectiveness of the resale registration statement. The warrants maintain a five-year expiration period from the registration statement's effective date, providing long-term financing flexibility for the company. The offering is scheduled to close around September 29, 2025, pending satisfaction of customary closing conditions.

H.C. Wainwright & Co. serves as the exclusive placement agent for this offering, bringing institutional expertise to the transaction. The company plans to allocate the net proceeds toward working capital requirements and other general corporate purposes. This capital infusion will support Lexaria's ongoing research and development initiatives for its DehydraTECH technology platform, which improves drug absorption through oral delivery methods.

The common stock shares are being offered pursuant to a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission on January 30, 2025. Investors can access the prospectus supplement and accompanying prospectus through the SEC's website once filed. The warrants and underlying shares issued in the private placement remain unregistered under Securities Act regulations, restricting their transferability except under specific exemption circumstances.

This financing development holds significance for the pharmaceutical industry as Lexaria's DehydraTECH platform addresses critical challenges in drug delivery efficiency. The technology has demonstrated potential to enhance bio-absorption rates and improve blood-brain barrier penetration for various therapeutic compounds. Successful implementation of this technology could lead to more effective oral medications with reduced side effects, potentially transforming treatment approaches across multiple disease categories.

The offering's structure, combining immediate equity financing with long-term warrant instruments, provides Lexaria with both immediate capital and future funding options. This approach demonstrates sophisticated financial planning that balances current operational needs with strategic growth considerations. For investors and industry observers, this transaction signals confidence in Lexaria's technology platform and its potential market applications.